Medical device cybersecurity has evolved from a technical concern into a core regulatory and patient safety requirement. As devices become increasingly connected, software driven and integrated with cloud infrastructure, cybersecurity risks now have direct implications for clinical outcomes. A vulnerability is no longer just an IT issue. It can affect device functionality, compromise diagnostic accuracy or disrupt therapy delivery. Regulators in both Europe and the United States have responded by embedding cybersecurity expectations into the broader safety and performance framework for medical devices. For manufacturers, this means cybersecurity must be treated as a fundamental component of product design, risk management and lifecycle compliance.
Why Cybersecurity Is a Patient Safety Issue
The primary driver behind regulatory focus on cybersecurity is patient safety. Medical devices increasingly rely on connectivity, third party software and real time data exchange. These features create potential entry points for cyber threats.
Cybersecurity failures can lead to device malfunction, incorrect therapy delivery or inaccurate diagnostic outputs. Loss of data integrity can affect clinical decision making, while loss of availability can disrupt healthcare delivery. Confidentiality breaches may expose sensitive patient data, creating both ethical and legal consequences. These risks demonstrate that cybersecurity is directly linked to safety and performance, not just operational resilience.
Cybersecurity Across the Device Lifecycle
Regulators expect cybersecurity to be managed across the entire product lifecycle rather than treated as a one time premarket activity. This includes design, development, verification, validation, deployment and post market monitoring.
Manufacturers must demonstrate that cybersecurity risks have been identified, assessed and mitigated throughout the lifecycle. This requires integration with risk management processes, continuous monitoring of vulnerabilities and the ability to implement updates and patches as new threats emerge. Lifecycle management ensures that devices remain secure as the threat landscape evolves.
EU MDR and IVDR Cybersecurity Expectations
In Europe, cybersecurity is embedded within the general safety and performance requirements of the MDR and IVDR. There is no standalone cybersecurity regulation. Instead, requirements are integrated into Annex I, which includes provisions for protection against unauthorised access, data integrity and system security.
Guidance such as IMDRF “Principles and Practices for Medical Device Cybersecurity” and MDCG 2019-16 provides additional clarification on expectations. Cybersecurity must be integrated into risk management under ISO 14971 and into the software lifecycle under IEC 62304. Secure design and development practices are required, along with verification and validation of security controls.
Documentation is distributed across the technical file and design documentation. Manufacturers must provide evidence of cybersecurity risk assessment, architecture design, testing and ongoing monitoring. Post market surveillance must include cybersecurity considerations, with continuous monitoring of vulnerabilities and timely updates reflected in documentation.
FDA Cybersecurity Expectations
The FDA takes a more structured and prescriptive approach to cybersecurity. A central requirement is the implementation of a Secure Product Development Framework, which spans the entire product lifecycle.
Premarket expectations include a cybersecurity management plan, detailed threat modelling, documentation of security architecture, a Software Bill of Materials and evidence demonstrating reasonable assurance of cybersecurity.
Post market expectations include vulnerability management processes, coordinated vulnerability disclosure programmes, defined remediation and patching capabilities and continuous monitoring of emerging threats. Cybersecurity documentation must be clearly structured within submissions and maintained within the Design History File.
Key Differences Between EU and FDA Approaches
Although both regulatory systems expect robust cybersecurity management, their approaches differ in structure and emphasis.
For The EU framework, cybersecurity requirements are embedded within broader safety and performance obligations, and evidence is distributed across technical documentation.
The FDA approach is more prescriptive. It requires specific documentation such as SBOMs and structured cybersecurity plans. Expectations for vulnerability management and disclosure are clearly defined.
Despite these differences, there is increasing convergence. Both frameworks emphasise lifecycle management, secure by design principles and integration with risk management systems and post market surveillance plays a central role in managing ongoing risk.
Core Technical Expectations
Regulatory expectations for cybersecurity are underpinned by several technical disciplines.
Threat modelling is a foundational activity. Manufacturers must identify assets such as data and device functionality, define potential threat actors and analyse attack vectors. The impact of these threats must be assessed in terms of patient safety and data confidentiality, integrity and availability. Threat models must be device specific, documented and maintained throughout the lifecycle.
Secure development practices must be integrated into the software lifecycle. This includes secure coding, code review, testing and management of third party components. Defence in depth strategies should be applied to reduce the likelihood of successful attacks.
Vulnerability management requires continuous monitoring of known vulnerabilities, including publicly disclosed issues and risks associated with third party software. The use of a Software Bill of Materials supports transparency and traceability. Manufacturers must define processes for identifying, assessing and remediating vulnerabilities.
Post market surveillance and patching capabilities are critical. Manufacturers must be able to monitor real world threats, develop and validate fixes and deploy updates safely. These activities must be linked to risk management and vigilance systems.
General security controls such as authentication, access control, encryption, network segregation and logging must be implemented to protect systems and data.
Common Regulatory Gaps and Mistakes
Despite clear expectations, many organisations struggle to implement effective cybersecurity strategies. Common issues include treating cybersecurity as separate from risk management, resulting in poor integration with ISO 14971 processes.
Threat modelling is often too generic and fails to consider realistic attack scenarios. This limits its usefulness in identifying meaningful risks.
Many manufacturers lack visibility of third party components and fail to maintain a complete Software Bill of Materials. This creates blind spots in vulnerability management.
Post market processes are frequently underdeveloped. Organisations may lack defined patching capabilities, vulnerability disclosure processes or structured monitoring systems.
Over reliance on penetration testing without supporting design evidence is another common issue. Testing alone does not demonstrate that cybersecurity has been systematically addressed.
A lack of lifecycle thinking is perhaps the most significant gap. Focusing only on premarket activities without planning for ongoing risk management leads to non compliance and increased risk over time.
Building a Compliant Cybersecurity Framework
To meet regulatory expectations, manufacturers should adopt a unified cybersecurity framework aligned with both EU and FDA requirements. This framework should integrate cybersecurity into risk management, software development and quality systems.
Early stage design decisions should incorporate secure by design principles. Threat modelling and risk assessment should inform architecture and control selection. Documentation should be structured to support both EU technical files and FDA submissions.
Post market processes must be defined and operational, including vulnerability monitoring, patching and disclosure. Cybersecurity should be treated as an ongoing responsibility rather than a one time activity.
Strategic Implications for Manufacturers
Cybersecurity is now a core element of regulatory strategy. It influences product design, development timelines, documentation requirements and post market obligations.
Organisations that treat cybersecurity as an integrated discipline will be better positioned to meet regulatory expectations, reduce risk and maintain market access. Those that approach it as an afterthought will face delays, increased scrutiny and potential compliance issues.
LFH supports medical device and digital health organisations in building integrated cybersecurity frameworks aligned with MDR, IVDR and FDA expectations. Our team helps manufacturers implement secure by design principles, develop compliant documentation and manage cybersecurity across the full product lifecycle with clarity and confidence.
FAQs – Medical Device Cybersecurity
Is cybersecurity a regulatory requirement for medical devices?
Yes, it is embedded within MDR, IVDR and FDA expectations as part of safety and performance requirements.
Does the EU have a dedicated cybersecurity regulation for medical devices?
No, cybersecurity requirements are integrated within MDR and IVDR frameworks.
What is a Software Bill of Materials?
It is a detailed list of software components used in a device, supporting transparency and vulnerability management.
Is cybersecurity required after a device is on the market?
Yes, continuous monitoring, patching and vulnerability management are required post market.
Do FDA and EU requirements differ significantly?
They differ in structure, but both expect lifecycle cybersecurity management and secure by design principles.
Is penetration testing sufficient to demonstrate cybersecurity compliance?
No, it must be supported by design evidence, risk management and lifecycle processes.
